
YOUR RESULTS

Summary Report


AN OVERVIEW BY TRUDIAGNOSTIC

CONTENT INDEX

ı OMICm Age Report	1
l DunedinPACE Report	3
I Immune Report	
ı Telomere Length Report	7
ı Fitness Age Report	9
l Smoking & Drinking Report	10
। Weight Loss Response Report	11
Extrinsic & Intrinsic Age Report	12



Aging has been scientifically proven to be the number one risk factor for major chronic diseases world-wide. Accelerated aging (having an older biological age than your calendar age) increases your **risk of disease with each year of discrepancy**, and having a younger biological age decreases these risks. Based on age, we can predict the following increase or decreased risk of Death, Cancer, Heart Disease, Stroke, Type 2 Diabetes, COPD, and Depression.







The Epigenetic Biomarker Proxies Driving Your Biological Age

We use epigenetic biomarker proxies to predict genomics, transcriptomics, proteomics, and metabolomics sum values that are positive for your aging, and some that are negative for your aging. In the graph below you will see the factors contributing to your aging the most. If a bar is above zero, its increasing your OMICm Age, if below zero, it is decreasing your OMICm Age.


Your Clinical Epigenetic Biomarker Proxies (EBP)



Your Metabolites Epigenetic Biomarker Proxies (EBP)



Your Protein Epigenetic Biomarker Proxies (EBP)






DunedinPACE of Aging

DunedinPACE Value



Population



Changes Over Time



ALGORITHM

PATIENT DATA MORBIDITY AND MORTALITY ASSOCIATIONS

RISK STATEMENT

DunedinPACE	1.13 Biological years per year	All-Cause Mortality (Beslsky et al., 2020)	If you are aging above a rate of 1.00, you would increase risk of death by 56% over the next 7 years.
		Chronic Disease (Beslsky et al., 2020)	If you are aging above a rate of 1.00, you would increase risk of chronic disease diagnosis by 54% over the next 7 years.

Significant Variation in Facial Aging

Female:

Male:



10 slowest-aging cohort members



10 average-aging cohort members



10 fastest-aging cohort members



10 slowest-aging cohort members



10 average-aging cohort members



10 fastest-aging cohort members





Immune Health

IMMUNE CELL TYPE	95% CONFIDENCE INTERVAL RANGE	YOUR PERCENTAGE	MEAN	SD	# OF STANDARD DEVIATIONS ABOVE OR BELOW MEAN	IS THIS HIGHER OR LOWER THAN ANTICIPATED?
Naïve CD4T	7.196%-7.35%	3.30%	7.273	0.0383	-1.04	Lower
Memory CD4T	5.14%-5.284%	1.33%	5.212	0.0361	-1.07	Lower
Memory CD8T	6.519%-6.691%	6.07%	6.605	0.0430	-0.12	Lower
Naïve CD8T	1.09%-1.16%	0.00%	1.125	0.0175	-0.64	Lower
Basophils	1.026%-1.056%	0.00%	1.041	0.0076	-1.37	Lower
B Memory	1.689%-1.785%	1.40%	1.737	0.0241	-0.14	Lower
Naïve B	2.207%-2.311%	0.00%	2.259	0.0260	-0.87	Lower
Regulatory T	0.604%-6.408%	3.60%	3.506	1.4510	0.06	Higher
Eosinophils	0.376%-0.424%	0.00%	0.400	0.0121	-0.33	Lower
Natural Killer	3.353%-3.459%	21.50%	3.406	0.0264	6.86	Higher
Neutrophils	62.899%-62.953%	54.11%	62.93	0.0136	-0.65	Lower
Monocyte	4.453%-4.567%	8.70%	4.510	0.0285	1.47	Higher




CD4/CD8 T Cell Ratio

CD4/CD8T cell ratio is incredibly informative on disease. A value between 1 and 4 is ideal. A value between 0 and 1 marks "inverted ratio". A low or inverted CD4/CD8 ratio is an immune risk phenotype and is associated with altered immune function, immune senescence, and chronic inflammation.

The prevalence of an inverted CD4/CD8 ratio increases with age. An inverted ratio is seen in 8% of 20-59 year olds and in 16% of 60-94 year olds. Women across all age groups are less likely to have an inverted ratio than their male counterparts.

Age, and hormone-related atrophy of the thymus is theorized to explain the differences between populations. Hormonal influence on the ratio is supported by a correlation between low Plasma Estradiol levels, high circulating CD8, and low CD4/CD8 ratios in women with premature ovarian failure.



We have been able to refer patients for additional testing to diagnose HIV, Chronic Lymphocytic Leukemia, and even individuals taking their Rapamycin at too high of a dose. If you see a low CD4/CD8 ratio, it is not an immediate cause for concern but we might recommend testing via traditional labs just in case. A value of 4+ marks hyperactivity or possible infection, autoimmunity or additional immune risk phenotypes.

CELL TYPE	REFERENCE RANGE	YOUR RATIO	MEAN	SD	# OF STANDARD DEVIATIONS ABOVE OR BELOW MEAN	IS THIS HIGHER OR LOWER THAN ANTICIPATED?
CD4/CD8 T Cell Ratio	1.00-4.00	0.76	2.59	0.074	-0.25	Lower

RATIO ABOUT THIS RATIO YOUR VALUE

Regulatory T Cells to Total T Lymphocytes (RegT/all other T Cells)	There is evidence that Tregs exhibit atheroprotective properties by suppression of autoreactive T cell responses or by secretion of anti-inflammatory cytokines (Pastrana et al., 2012). Thus this might be a marker for cardiovascular disease. (www.sciencedirect.com)	0.34
Adaptive to Innate Immune (A/A Ratio)	The adaptive-to-innate immune ratio (A/I ratio) has been linked to response to several types of immunotherapy.	0.44



Other Immunosenescence Ratios

RATIO	ABOUT THIS RATIO	NORMATIVE RATIO	YOUR VALUE
Neutrophil to Lymphocyte	The NLR is simply the number of Neutrophils divided by the number of Lymphocytes. Under physiologic stress, the number of Neutrophils increases, while the number of Lymphocytes decreases. The NLR combines both of these changes, making it more sensitive than either alone: Effect of Physiologic Stress on the NLR: The Number of Neutrophils Lymphocytes Endogenous cortisol and catecholamines may be major drivers of the NLR. Increased levels of cortisol are known to increase the neutrophil count while simultaneously decreasing the lymphocyte count. Thus, NLR is not solely an indication of infection or inflammation. Any cause of physiologic stress may increase the NLR (e.g. hypovolemic shock).	Neutrophil-to-Lymphocyte ratio (NLR) reflects the amount of physiologic stress. The optimal cutoff value will vary depending on the specific patient population and disease state. The numbers provided above are. intended merely to provide a general concept of NLR interpretation.	3.45
Monocyte to Lymphocyte	MLR (Monocyte to Lymphocyte ratio) has demonstrated to be a novel hematological and inflammatory parameter. MLR is associated with various diseases, such as community-acquired pneumonia, axial spondylarthritis, and coronary angiography, as well as the systemic inflammatory response, which reflects the abnormal immune status of diseases.	The mean Neutrophil-toLymphocyte ratio in the whole population was 1.70±0.70 (Range: 8.38, Min: 0.23, Max: 8.61), mean lymphocyte-to-monocyte ratio was 11.15±3.14 (Range:23.21, Min:3.46, Max:26.67), and mean platelet-to-lymphocyte ratio was 117.05±47.73 (Range:93.60, Min:19.11, Max:1598.77).	1.81



Telomere Length

Telomere Length:

6.8


Kb

If we were to estimate your biological age **strictly from your telomere measurement,** we would anticipate your age to be:

Your Average telomere prediction length:



Telomere Length Based on Biological Age Prediction:



This puts you in the:

6.8 kb

59.48th Percentile





ALGORITHM PATIENT MORBIDITY AND MORTALITY
DATA ASSOCIATIONS RISK STATEMENT


Telomere 6.8
Kilobase
Unit

At your chronological age of 71.37, your telomeres are longer than 59.48th% of people. who share the same chronological age as you.

Shorter telomeres are not only associated with age but with disease too. Shorter telomere length and low telomerase activity are correlated with several chronic preventable diseases.



Fitness Age



IFor every one year older OMICm FitAge is, there is an average **0.29 decrease in relative grip strength and 0.32 increase in BMI.** OMICm FitAge has estimated that high-fit individuals (classified through VO2max) have a **1.5 to 2.0 younger biological age** compared to low/medium fit individuals in females and males, respectively. Younger OMICm FitAge was associated with better memory test performance, emphasizing the beneficial role of physical exercise on cognitive health.



OMICm FitAge is impacted by:



Maximum hand grip strength (GripMax) a measurement of force taken in kg and is used to measure the age-associated decline in terms of muscle strength.




Gait speed, also known as walking speed, is measured in meters per second.




Maximal oxygen uptake, or VO2max, is a measure of cardiovascular health and aerobic endurance.




Forced expiratory volume, also known as FEV1, measures lung function by determining the amount of air forced from the lungs in one second.




Your Grip Strength Epigenetic Biomarker Proxy is <u>44.80</u>. This puts you scoring higher than <u>99.04%</u> of the population with a similar reported age and sex.



Your V02Max Epigenetic Biomarker Proxy is **45.93.** This puts you scoring higher than **93.22%** of the population with a similar reported age and sex.



Your Gait Speed Epigenetic Biomarker Proxy is <u>1.75</u>. This puts you scoring higher than <u>71.59%</u> of the population with a similar reported age and sex.



Your FEV1 Epigenetic Biomarker Proxy is **2.21.** This puts you scoring higher than **41.53%** of the population with a similar reported age and sex.



Smoking & Drinking

Smoking and Disease Risk

AHRR (cg05575921) Average Beta Value %:

Your Epitype Value: 88%


The impact that tobacco smoke exposure has on the epigenome is based on the level of methylation at the AHRR gene locus cg05575921.

Your DNA methylation score was **88%** at the AHRR locus, meaning that your methylation score aligns with the status of **non-smoker**, putting you at **Low**

risk for developing smoking-related conditions.



[64%-100%] No Epigenetic Risk



On your intake survey, you self-reported your drinking status as **Never**. With our custom epigenetic biomarker proxy, you are in the **0.55th** percentile. This means your score is higher than **0.55%** of the population we have tested.

*Those who marked self-reported drinking as "Not Applicable" were assumed to have no drinking status and have been combined with data from "Never" status.





Weight Loss Response

CPG SITE	GENE	β - VALUE RESPONDERS	YOUR SCORE	RESPONSE STATUS
cg15500865	PON3	0.072	0.04	Hypomethlyated
cg25161512	PON3	0.115	0.05	Hypomethlyated
cg11435506	PON3	0.165	0.02	Hypomethlyated
cg03301582	PON3	0.120	0.09	Hypomethlyated
cg08898155	PON3	0.163	0.01	Hypomethlyated
cg04080282	PON3	0.324	0.17	Hypomethlyated
cg26457160	PON3	0.490	0.60	Hypermethylated
cg10329418	PON3	0.252	0.07	Hypomethlyated
cg27166921	PON3	0.253	0.33	Hypermethylated
cg24750391	PON3	0.355	0.36	Hypermethylated
cg08461772	PON3	0.418	0.22	Hypomethlyated


RISK REPORT	PATIENT OUTCOMES	SUMMARY	IMPACT	ADDITIONAL NOTE
Weight Loss Response	No response	Your DNA methylation scores at the above loci indicate you are a Non responder for weight loss treatment utilizing a hypocaloric diet. This means a calorie deficit diet passably works as your weight loss strategy.	If your DNA methylation score puts you in the category of non-responder or intermediate responder then a hypocaloric diet might not be the best treatment option for you. If you are a responder, that means a hypocaloric diet has a greater chance of positively impacting your weight loss goals.	Studies on these particular CpG loci have concluded that some individuals have a better response to a calorie deficit diet than others. This may indicate why weight loss has been difficult to achieve and can provide insight into finding the best weight loss strategy.







Intrinsic & Extrinsic Age

Intrinsic Epigenetic Age






Changes Over Time



Extrinsic Epigenetic Age





Changes Over Time



